ABT-925 free base
ABT-925, also known as A-37203, BSF-201640; DAT-201; Lu-201640; and A-437203, is a selective dopamine D3 receptor (DRD3) antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors. ABT-925 was tested in schizophrenia. ABT-925 is a selective dopamine D₃ receptor antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors.
Supplier | Ace Therapeutics |
---|---|
Product # | SMD1364 |
CAS # | 220519-06-2 (free base) |
Pricing | Customizable size, Inquiry |
Synonym | A 37203; A-37203; A37203; A 437203; A437203; A-437203; ABT 925; ABT925; ABT-925; BSF 201640; BSF201640; BSF-201640; DAT 201; DAT201; DAT-201; Lu 201640; Lu201640; Lu-201640; |
Product Category | Lab-use Small Molecule Drugs |
Chemical Formula | C20H27F3N6OS |
Exact Mass | 456.1919 |
Molecular Weight | 456.5322 |
Elemental Analysis | C, 52.62; H, 5.96; F, 12.48; N, 18.41; O, 3.50; S, 7.02 |
IUPAC/Chemical Name | 2-((3-(4-(2-(tert-butyl)-6-(trifluoromethyl)pyrimidin-4-yl)piperazin-1-yl)propyl)thio)pyrimidin-4(3H)-one |
InChi Key | KXVAICSRMHXLJN-UHFFFAOYSA-N |
InChi Code | InChI=1S/C20H27F3N6OS/c1-19(2,3)17-25-14(20(21,22)23)13-15(26-17)29-10-8-28(9-11-29)7-4-12-31-18-24-6-5-16(30)27-18/h5-6,13H,4,7-12H2,1-3H3,(H,24,27,30) |
SMILES Code | O=C1NC(SCCCN2CCN(C3=NC(C(C)(C)C)=NC(C(F)(F)F)=C3)CC2)=NC=C1 |
Appearance | Solid powder |
Purity | >98% (or refer to the Certificate of Analysis) |
Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
Storage Condition | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
Solubility | Soluble in DMSO, not in water |
Shelf Life | >2 years if stored properly |
Drug Formulation | This drug may be formulated in DMSO |
Stock Solution Storage | 0 - 4℃ for short term (days to weeks), or -20℃ for long term (months). |
HS Tariff Code | 2934.99.9001 |
Availability | 2 Weeks |